Top in GI: Magnetic sphincter augmentation, the evolution of IBD

A recent study showed that magnetic sphincter augmentation was safe and resulted in long-term symptom improvement among patients with gastroesophageal reflux disease. It was the top story in gastroenterology last week.

Another top story was about a commentary on the evolution of inflammatory bowel disease (IBD) and how a better understanding of it can help researchers predict a rise in prevalence.

Read these and more top stories in gastroenterology below:

Magnetic sphincter augmentation linked with long-term safety, efficacy for GERD

Magnetic sphincter augmentation resulted in long-term efficacy regarding symptom improvement, decreased drug dependency and reduced esophageal acid exposure in gastroesophageal reflux disease, according to recent data. Read more.

Commentary: Understand the evolution of IBD

In this commentary, Gilaad G. Kaplan, MD, of the department of medicine at the University of Calgary, Alberta, Canada, discusses the four epidemiological stages of IBD and reviews the forecast of disease prevalence and how disease penetration through a population evolves over time. Read more.

Cryoballoon ablation safe, effective for neoplastic Barrett’s esophagus

Cryoballoon ablation was safe and effective in patients with neoplastic Barrett’s esophagus, according to a study published in the American Journal of Gastroenterology. Read more.

Predictive model may assist patients, providers in decision making for advanced neoplasia

A predictive model for advanced colorectal neoplasia may help increase colorectal cancer screening adherence, according to a study published in Gut. Read more.

Xeljanz extended induction effective in UC

A majority of patients with ulcerative colitis treated with Xeljanz (tofacitinib, Pfizer) achieved clinical response after 8 or 16 weeks of induction, according to study results. Read more.